Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Ziprasidone (CP 88059; CP-88,059; CP-88,059-01; Geodon; Zeldox; Zipwell) HCl, the hydrochloride salt of Ziprasidone, is a novel and potent dopamine and serotonin (5-HT) receptor antagonist with antipsychotic effects. It is authorized for the treatment of acute mania, mixed states linked to bipolar disorder, and schizophrenia and bipolar illness. When treating schizophrenia patients who respond best to treatment consisting solely of ziprasidone, its intramuscular injection form is authorized for use in cases of acute agitation. According to theories about ziprasidone's mode of action, serotonin type 2 (5HT2) and dopamine type 2 (D2) antagonistic interactions together mediate the drug's effectiveness in treating schizophrenia. The exact mechanism by which ziprasidone treats bipolar disorder is unknown, as it is with other medications that are effective in treating the condition.
Targets |
Rat 5-HT2A ( Ki = 0.42 nM ); Rat 5-HT1A Receptor ( Ki = 3.4 nM ); Rat D2 Receptor ( Ki = 4.8 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
Cell Line: HEK-293 cells
Concentration: 0-500 nM Incubation Time: 150 seconds Result: Blocked wild-type hERG current in a voltage- and concentration-dependent manner (IC50 = 120 nm). |
|
Animal Protocol |
Eight-week-old female Sprague-Dawley rats weighing 200 to 250 g
20 mg/kg Oral gavage; 20 mg/kg; once daily; 7 weeks |
|
References |
Molecular Formula |
C21H22CL2N4OS
|
|
---|---|---|
Molecular Weight |
449.4
|
|
Exact Mass |
448.09
|
|
Elemental Analysis |
C, 56.13; H, 4.93; Cl, 15.78; N, 12.47; O, 3.56; S, 7.13
|
|
CAS # |
122883-93-6
|
|
Appearance |
Solid powder
|
|
SMILES |
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.Cl
|
|
InChi Key |
NZDBKBRIBJLNNT-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C21H21ClN4OS.ClH/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;/h1-4,11,13H,5-10,12H2,(H,23,27);1H
|
|
Chemical Name |
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2252 mL | 11.1259 mL | 22.2519 mL | |
5 mM | 0.4450 mL | 2.2252 mL | 4.4504 mL | |
10 mM | 0.2225 mL | 1.1126 mL | 2.2252 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03781115 | Recruiting | Drug: Ziprasidone Drug: Olanzapine |
Schizophrenia | University of Arizona | November 20, 2017 | Phase 1 |
NCT01714011 | Completed | Drug: Ziprasidone Drug: Aripiprazole |
Schizophrenia | University of Malaya | May 2009 | Phase 4 |
NCT01581866 | Completed | Drug: Ziprasidone Hydrochloride | Healthy | Dr. Reddy's Laboratories Limited | November 2004 | Phase 1 |
NCT01581879 | Completed | Drug: Ziprasidone Hydrochloride | Healthy | Dr. Reddy's Laboratories Limited | November 2004 | Phase 1 |
NCT01198353 | Completed | Drug: Ziprasidone | Schizoaffective Disorder Schizophrenia |
Soonchunhyang University Hospital | September 2010 | Phase 4 |